<DOC>
	<DOCNO>NCT02765516</DOCNO>
	<brief_summary>The objective study utilize information association genetic predisposition pertain multiple single nucleotide polymorphism ( SNPs ) degree responsiveness low-density lipoprotein cholesterol ( LDL-C ) lowering plant sterol ( PS ) . The predictive potential SNPs associate PS responsiveness evaluate use randomize human intervention trial examine responsiveness lower blood LDL-C level PS intervention .</brief_summary>
	<brief_title>Genetic Basis Prediction Non-responders Dietary Plant Sterol Intervention</brief_title>
	<detailed_description>On average plant sterol ( PS ) consumption 2-3 gram day lead ~10 % decrease low-density lipoprotein cholesterol ( LDL-C ) . However , inter-individual response PS consumption varies , individual show low reduction LDL-C level , even show increase level . Determining factor predict direction response LDL-C PS would helpful identifying individual consume PS individual seek another method treat hypercholesterolemia . The objective research proposal test priori predictive potential combination three single nucleotide polymorphism ( SNPs ) , i.e. , genosets , previously associate response PS post-hoc manner . A clinical trial priori recruitment participant base genoset test LDL-C response PS consumption use randomize , double blind , placebo control crossover design propose .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Fasting LDLC concentration &gt; 3.0 &lt; 4.9 mmol/L Fasting glucose concentration &lt; 6.1 mmol/L Fasting triglyceride concentration &lt; 4.52 mmol/L Genoset require : ApoE ε2/ CYP7A1 rs3808607 T/T ( n=8 ) ; ApoE ε2/ CYP7A1 rs3808607 G/ ( n=8 ) ; ApoE ε3/ε3 CYP7A1 rs3808607 T/T ( n=8 ) ; ApoE ε3/ε3 CYP7A1 rs3808607 T/G ( n=8 ) ; ApoE ε3/ε3 CYP7A1 rs3808607 G/G ( n=8 ) ; ApoE ε4/ CYP7A1 rs3808607 T/T ( n=8 ) ; ApoE ε4/ CYP7A1 rs3808607 T/G ( n=8 ) ; ApoE ε4/ CYP7A1 rs3808607 G/G ( n=8 ) Consuming , consume last 3 month , medication nutritional supplement know affect lipid metabolism ( cholestyramine , colestipol , niacin , clofibrate , gemfibrozil , probucol , HMGCoA R inhibitor , methotrexate , high dose dietary supplement , fish oil capsule plant sterol stanol ) , dietary restriction would prevent consume trial treatment BMI &gt; 40 Must selfreported weight gain loss great 3 kg past three month Phytosterolemic History active cardiovascular disease include stroke , congestive heart failure , myocardial infarction , unstable angina pectoris , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , temporal ischemic attack , anemia , abnormal electrolyte , proteinuria , abnormal liver , kidney thyroid function Type 1 type 2 diabetes , history cancer malignancy last 5 year , metabolic disease , gastrointestinal disorder clinically significant disease/disorder could interfere result study safety participant . Uncontrolled hypertension systolic blood pressure &gt; 160mm Hg diastolic blood pressure &gt; 100mm Hg Smoker , tobacco/snuff/nicotine user , recreational drug user Consume 14 alcoholic beverage week Participants pregnant plan become pregnant trial period lactate mother Participants exclude clinically significant biochemistry define : LDLC &lt; 3.0mmol/L &gt; 4.9 mmol/L ; TC &gt; 6.2 mmol/L ; fast glucose : &gt; 6.1 mmol/ l , fast TG &gt; 4.52 mmol/L ; AST &gt; 100 U/L ; ALT &gt; 100 U/L clinically significant abnormality hematology and/or biochemistry investigator 's discretion Patients unstable serious illness , example , dementia , terminal illness , recent bereavement , recent significant medical diagnosis also exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>